Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2
CA 2299270 A1 · Owner: Bouillaud, Frederic · Inventors: Ricquier, Daniel; Rial Zueco, Eduardo; Bouillaud, Frederic
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to the use of a compound of the retinoïd type particularly retinoïc acid for the preparation of a medicament capable of modulating in vivo the decoupling activity of decoupling proteins. These compounds can be used conveniently for the treatment of diseases associated to an increase or reduction of the activity of decoupling proteins. According to a preferred embodiment, the retinoïc acid will be used for the treatment of diseases associated to a reduction of the decoupling activity of the protein UCP2 such as for example obesity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 5, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 5, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 5, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.